Veracyte VCYT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $541.74M+16.9% | $517.15M+16.0% | $495.14M+16.4% | $479.13M+19.9% | $463.39M+23.4% | ||
| —— | —— | —— | —— | —— | ||
| $384.18M+21.9% | $362.53M+21.6% | $339.31M+19.4% | $327.04M+24.4% | $315.19M+30.9% | ||
| 70.9%+2.9pp | 70.1%+3.2pp | 68.5%+1.7pp | 68.3%+2.5pp | 68%+3.9pp | ||
| $80.19M+12.9% | $70.81M+2.2% | $69.26M+0.8% | $70.85M+10.0% | $71.05M+17.4% | ||
| $102.87M+7.0% | $100.17M+5.0% | $99.05M+3.3% | $97.21M-0.4% | $96.11M-3.1% | ||
| $100.66M-14.8% | $110.78M+0.2% | $120.33M+11.9% | $118.79M+21.1% | $118.21M+29.4% | ||
| —— | —— | —— | —— | —— | ||
| $306.66M+5.2% | $304.76M+8.1% | $314.56M+2.2% | $313.21M-5.1% | $291.48M-9.1% | ||
| $77.52M+227% | $57.78M+258% | $24.76M+205% | $13.83M+121% | $23.7M+130% | ||
| 14.3%+9.2pp | 11.2%+7.6pp | 5%+10.5pp | 2.9%+19.7pp | 5.1%+26.4pp | ||
| $13.23M+9.2% | $10.42M+0.9% | $6.99M-54.6% | $15.87M+26.9% | $12.11M+27.2% | ||
| $90.75M+159% | $68.2M+165% | $31.01M+480% | $28.97M+153% | $35.08M+150% | ||
| —— | —— | —— | —— | —— | ||
| $88.01M+166% | $66.35M+175% | $30.32M+427% | $26.34M+149% | $33.05M+148% | ||
| 16.2%+9.1pp | 12.8%+7.4pp | 6.1%+8.3pp | 5.5%+19.0pp | 7.1%+25.3pp | ||
| $1.08+163% | $0.82+173% | $0.38+371% | $0.33+145% | $0.41+144% | ||
| $99M+111% | $79.19M+100.0% | $47.13M+2,356,250% | $36.81M+187% | $46.93M+187% | ||
| 18.3%+8.1pp | 15.3%+6.4pp | 9.5%+9.5pp | 7.7%+18.3pp | 10.1%+24.5pp | ||
| $77.52M+227% | $57.78M+258% | $24.76M+205% | $13.83M+121% | $23.7M+130% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Veracyte's profit margins?
- Gross margin is 70.9% and operating margin is 14.3%, with a 16.2% net margin.
- Where does Veracyte's income statement data come from?
- Every line is extracted from Veracyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.